Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan

被引:8
|
作者
Sacramento Diaz-Carrasco, Maria [1 ]
Olmos, Raquel [1 ]
Blanquer, Miguel [2 ]
Velasco, Javier [1 ]
Sanchez-Salinas, Andres [2 ]
Maria Moraleda, Jose [2 ]
机构
[1] Virgen de la Arrixaca Hosp, Dept Hosp Pharm, Murcia, Spain
[2] Virgen de la Arrixaca Hosp, Dept Hematol, Murcia, Spain
关键词
Busulfan; Clonazepam; Hematopoietic stem cell transplantation; HSCT; Seizure prophylaxis; ACUTE-LEUKEMIA; CHILDREN; LORAZEPAM; PHARMACOKINETICS;
D O I
10.1007/s11096-013-9768-x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Due to their favorable toxicity profile and lack of interactions, benzodiazepines have been proposed as prophylaxis of busulfan induced seizures. Although they are broadly used in pediatric patients, the experience in adults is limited. Objective To describe the effectivity for seizure prophylaxis of the fixed 1 mg every 8 h (q8h) i.v. clonazepam dosing in adult patients receiving high dose i.v busulfan, as part of the hematopoietic progenitors transplant conditioning regimen. Methods Retrospective, observational study, from January 2008 to June 2012. Patients over 15 years old that had received high dose busulfan and prophylaxis with 1 mg q8h i.v. clonazepam from 12 h before the first dose of busulfan to 24 h after the last one were selected. The primary endpoint was the occurrence of seizures until 72 h after finishing conditioning. Results Thirty-three patients, 13 female and 20 male, median age 48, were included. Autologous transplant was performed in 17 patients and allogeneic in 16. Busulfan dose was 3.2 mg/kg every 24 h with a variable duration of 2-4 days. No seizures were recorded. Conclusion The 1 mg q8h i.v. clonazepam fixed schedule is easily administered and is effective for the prevention of high dose busulfan induced seizures in adult patients.
引用
收藏
页码:339 / 343
页数:5
相关论文
共 50 条
  • [21] Evaluation of Limited Sampling Methods for Oral Busulfan Pharmacokinetic Monitoring in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation
    Bouchard, Philippe
    Bilodeau, Sarah
    Alain, Karine
    Vadnais, Barbara
    Franco, Martin
    Turgeon, Jacques
    Michaud, Veronique
    THERAPEUTIC DRUG MONITORING, 2016, 38 (03) : 414 - 418
  • [22] Optimal Prevention of Seizures Induced by High-Dose Busulfan
    Eberly, Andrea L.
    Anderson, Gail D.
    Bubalo, Joseph S.
    McCune, Jeannine S.
    PHARMACOTHERAPY, 2008, 28 (12): : 1502 - 1510
  • [23] PHARMACOKINETICS OF HIGH-DOSE BUSULFAN IN RELATION TO AGE AND CHRONOPHARMACOLOGY
    HASSAN, M
    OBERG, G
    BEKASSY, AN
    ASCHAN, J
    EHRSSON, H
    LJUNGMAN, P
    LONNERHOLM, G
    SMEDMYR, B
    TAUBE, A
    WALLIN, I
    SIMONSSON, B
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 28 (02) : 130 - 134
  • [24] Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2-and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen
    Huang, Jingjing
    Li, Ziwei
    Liang, Wu
    Chen, Bing
    Hu, Jiong
    Yang, Wanhua
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (05) : 638 - 645
  • [25] Population pharmacokinetic study of a test dose oral busulfan in Japanese adult patients undergoing hematopoietic stem cell transplantation
    Yasushi Takamatsu
    Noriaki Sasaki
    Kentaro Ogata
    Eiji Yukawa
    Shiro Jimi
    Shuuji Hara
    Kazuo Tamura
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 1203 - 1207
  • [26] Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation
    Wada, Fumiya
    Nishikori, Momoko
    Hishizawa, Masakatsu
    Watanabe, Mitsumasa
    Aiba, Akiko
    Kitano, Toshiyuki
    Shimazu, Yayoi
    Shindo, Takero
    Kondo, Tadakazu
    Takaori-Kondo, Akifumi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 112 (05) : 609 - 613
  • [27] Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation
    Fumiya Wada
    Momoko Nishikori
    Masakatsu Hishizawa
    Mitsumasa Watanabe
    Akiko Aiba
    Toshiyuki Kitano
    Yayoi Shimazu
    Takero Shindo
    Tadakazu Kondo
    Akifumi Takaori-Kondo
    International Journal of Hematology, 2020, 112 : 609 - 613
  • [28] Individualizing Oral Busulfan Dose After Using a Test Dose in Patients Undergoing Hematopoietic Stem Cell Transplantation: Pharmacokinetic Characterization
    Effting, Cristiane
    Arantes, Adriano de Moraes
    Queiroz Labre, Luciana V.
    Carneiro, Wilsione J.
    de Oliveira Neto, Jeronimo R.
    Bariani, Cesar
    Rodrigues, Caroline R.
    Rodrigues, Andryne R.
    Cunha, Luiz C.
    THERAPEUTIC DRUG MONITORING, 2015, 37 (01) : 66 - 70
  • [29] INFLUENCE OF PROPHYLACTIC ANTICONVULSANT THERAPY ON HIGH-DOSE BUSULFAN KINETICS
    HASSAN, M
    OBERG, G
    BJORKHOLM, M
    WALLIN, I
    LINDGREN, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 33 (03) : 181 - 186
  • [30] Population Pharmacokinetic Analysis of Busulfan in Japanese Pediatric and Adult HCT Patients
    Kawazoe, Atsuko
    Funaki, Tomoo
    Kim, Seongryul
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (09) : 1196 - 1204